Q3 2025 EPS Estimates for Exact Sciences Co. (NASDAQ:EXAS) Reduced by William Blair

Exact Sciences Co. (NASDAQ:EXAS) – William Blair cut their Q3 2025 earnings per share (EPS) estimates for shares of Exact Sciences in a report issued on Monday, June 3rd. William Blair analyst A. Brackmann now expects that the medical research company will post earnings per share of $0.00 for the quarter, down from their previous estimate of $0.04. William Blair has a “Outperform” rating on the stock. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.15) per share.

Several other research analysts also recently weighed in on EXAS. Canaccord Genuity Group decreased their price target on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Citigroup cut their price target on Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Jefferies Financial Group began coverage on shares of Exact Sciences in a report on Monday. They issued a “buy” rating and a $75.00 target price for the company. TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Finally, BTIG Research decreased their price objective on shares of Exact Sciences from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $93.07.

Exact Sciences Trading Up 4.8 %

Shares of EXAS stock opened at $45.55 on Tuesday. The stock has a market capitalization of $8.41 billion, a P/E ratio of -34.51 and a beta of 1.26. The company has a current ratio of 1.64, a quick ratio of 1.45 and a debt-to-equity ratio of 0.66. The firm’s 50 day moving average is $59.80 and its 200 day moving average is $63.02. Exact Sciences has a 12-month low of $43.30 and a 12-month high of $100.77.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. The business had revenue of $637.52 million during the quarter, compared to analyst estimates of $624.95 million.

Insiders Place Their Bets

In other news, CEO Kevin T. Conroy sold 1,155 shares of Exact Sciences stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total value of $69,473.25. Following the sale, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Kevin T. Conroy sold 1,155 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the completion of the transaction, the chief executive officer now directly owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the sale, the executive vice president now owns 71,787 shares in the company, valued at approximately $5,025,090. The disclosure for this sale can be found here. Insiders have sold a total of 5,498 shares of company stock worth $370,105 in the last 90 days. 1.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EXAS. Vanguard Group Inc. lifted its stake in shares of Exact Sciences by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 17,740,092 shares of the medical research company’s stock valued at $1,225,131,000 after purchasing an additional 180,341 shares during the last quarter. Capital World Investors raised its holdings in Exact Sciences by 74.4% during the 1st quarter. Capital World Investors now owns 13,025,313 shares of the medical research company’s stock valued at $899,528,000 after buying an additional 5,557,168 shares during the period. Artisan Partners Limited Partnership lifted its position in Exact Sciences by 12.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company’s stock worth $330,711,000 after buying an additional 508,764 shares during the last quarter. Champlain Investment Partners LLC boosted its stake in Exact Sciences by 175.3% during the first quarter. Champlain Investment Partners LLC now owns 2,258,235 shares of the medical research company’s stock worth $155,954,000 after buying an additional 1,438,010 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Exact Sciences by 11.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,858,380 shares of the medical research company’s stock valued at $137,483,000 after acquiring an additional 192,372 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.